David W Scott

Spyryx Biosciences, Inc.

$1,247,544

Attributed

$1,247,544

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY2017–25

$2M$1.5M$1M$500K$0

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$1,247,544 · 2

By mechanism

R44$1,024,945 · 1

R43$222,599 · 1

Top collaborators

No co-investigators on record.

Others in their field

Other Emerging Leaders on “Nebulizer”

Matthew Reed · Nob Hill Therapeutics, Inc.$4,021,634
Gaurav Sahay · Oregon State University$3,918,234
Qi Zhou · Purdue University$3,430,421
Lyndsey Linke · Sivec Biotechnologies, Llc$3,048,652
Bryce Beverlin II · Quench Medical, Inc.$2,701,828
Chiara Bellini · Northeastern University$2,314,713

Research focus

NebulizerGrantCostMucous Body SubstanceTissuesInfectionCessation Of LifeClinical TrialsEpitheliumLungPreventRattusValidationPharmaceutical PreparationsAdultCellsClinicBindingAnimal ModelDoseAwardAnti-Viral TherapyAgreementAnti-Viral Agents

Grant awards (2)

Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV$1,024,945

R44 · FY2025 · AI · contact PI

Validation of SPX-101 as a candidate for the treatment of cystic fibrosis$222,599

R43 · FY2017 · HL · contact PI